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Direct current (DC) cardioversion is now a common,
accepted, outpatient procedure that treats a growing number
of patients with symptomatic atrial flutter and atrial fibril-
lation (AF), but complications can occur. Stroke following
cardioversion is the most feared consequence of this bene-
ficial and effective therapy.
Thromboemboli are a known complication of chronic
AF, and acute reversion of AF to sinus rhythm (SR) (by a
drug or an electric shock) can increase the risk 10-fold.
Most embolic episodes occur within 10 days of cardiover-
sion (1). The cause for this increased risk is only postulated.
The incidence of clinically apparent thromboemboli is only
the tip of the iceberg because many thrombi that become
lodged in blood vessels throughout the body may go
undetected (Fig. 1) (2).
See page 926
The use of anticoagulants to protect patients with AF
from thromboemboli is not new (3). Data from placebo-
controlled randomized trials demonstrate the clear benefit
of long-term anticoagulation in high-risk patients with AF.
A compilation of data from five major multicenter trials shows
a 67% average risk reduction with warfarin given long term
based on an intention-to-treat analysis, but the benefits may
really be greater than that. The safety and efficacy of warfarin
anticoagulation for chronic AF in high-risk patients are indis-
putable, notwithstanding the few students of the literature who
have attempted to cast doubt on its utility (4).
Persuasive data demonstrate unequivocally that warfarin
anticoagulation offsets the augmented risk of thromboem-
boli after DC cardioversion, but several important questions
remain: 1) Is it safe for a patient with AF to undergo
cardioversion in the first 48 h without anticoagulation? 2) Is
it safe to cardiovert atrial flutter without anticoagulation? 3)
What is the level of anticoagulation needed to ensure safety
during and after cardioversion? 4) Is heparin or low molec-
ular weight heparin as safe and effective as warfarin antico-
agulation to protect against thromboemboli? 5) What is the
proper anticoagulation regimen required for those whose
cardioversion attempt is guided by transesophageal echocar-
diography (TEE)?
In this issue of the Journal, Gallagher et al. (5) address, in
part, these important challenging issues. Their article un-
derscores the crucial importance of “proper” anticoagulation
for cardioversion of atrial arrhythmias and amplifies key
issues. As such, proper anticoagulation is now in better
focus.
Is it safe for a patient with AF to undergo cardioversion
in the first 48 h (or even 7 days) without anticoagula-
tion? It appears safe for patients with 48 h of AF to
undergo cardioversion even without anticoagulation. Several
trials demonstrated a low risk for thromboemboli even when
a patient with short-term AF did not undergo anticoagula-
tion at the time of cardioversion or soon thereafter. Weigner
et al. (6) showed that, of 1,822 patients with AF, 375
episodes lasted 48 h and, of these, only three (0.8%),
converting spontaneously to SR, had thromboembolic
events. Arguably, this represents a moderate risk for an elective
procedure. Gallagher et al. (5) even more strongly support the
concept that cardioversion of short-term AF is associated with
a low risk of thromboemboli. Only one event occurred in 443
patients (0.22% or 0.28% for those not receiving prolonged
anticoagulation) who had an atrial arrhythmia lasting 2 days or
less. Unfortunately, the data in this48-h group are difficult to
assess in the report of Gallagher et al. (5) because the use of
anticoagulation and the number with atrial flutter are not clear.
This issue is even more cloudy in patients with atrial arrhyth-
mias lasting up to 7 days; policies varied among hospitals.
It appears acceptable to withhold anticoagulation in patients
undergoing cardioversion for an atrial arrhythmia lasting 2 days
or less, as is already recommended (7). The concern remains:
how certain is the arrhythmia onset? Risks may also increase if
there are “sputtering,” self-terminating AF episodes before
cardioversion. Even so, atrial arrhythmias of short duration can
be cardioverted safely without anticoagulation.
Is it safe to cardiovert atrial flutter without anticoagula-
tion? Apparently it is not. Until recently, few long-term
studies indicated a benefit of warfarin in preventing throm-
boemboli in atrial flutter, but concern was raised several
years ago (8). Data from our laboratory (9) and others (10)
have shown that chronic atrial flutter is associated with
long-term risk of thromboemboli, similar to AF, and that
the risk is reduced by maintaining effective warfarin antico-
agulation. Biblo et al. (11) reviewed 8 years of retrospective
Medicare population data and showed that the risks of
stroke are substantial in patients with an atrial flutter
diagnosis, although perhaps not at the level of AF.
Thromboemboli can occur from cardioversion of atrial
flutter (12). Thrombi and spontaneous echo contrast have
been observed by TEE in atrial flutter (13–15). Left atrial
stunning can occur after ablation or cardioversion of atrial
flutter with return to SR (16,17). In our laboratory (18),
TEE, before cardioversion of atrial flutter, revealed abnor-
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mal left atrial transport. The mechanism responsible for
thromboemboli in atrial flutter, and its conversion to SR,
may differ from that for atrial fibrillation, but the risks are
nevertheless noteworthy.
Gallagher et al. (5) confirm that thromboemboli can
occur with cardioversion of atrial flutter. The actual risk is
difficult to determine, because the policies regarding anti-
coagulation, the time to enrollment in the study, the length
of episode, the underlying cardiac diagnoses, and other
undetermined factors were not controlled. Only 21.6% with
atrial flutter lasting longer than 2 days had an international
normalized ratio (INR) 2.5 at the time of cardioversion.
Those with INR values 2.5 had no embolic complications
compared with those not receiving anticoagulation (0.9%
risk) or those taking ineffective anticoagulation (0.5% risk;
p  nonsignificant).
The FLASIEC multicenter study (19) suggested that the
risk for cardioversion of atrial flutter might be lower than for
AF and that the risk of an atrial thrombus was “small” (left
atrial appendage thrombus in 1.6% and right atrial throm-
bus in 1%). An embolic event occurred after cardioversion in
2 of 93 (2.2%) patients (1 month follow-up in 78 and
restoration of SR in 62 patients). Thirty-four percent
underwent anticoagulation with warfarin or heparin.
Elhendy et al. (20) showed that the 30-day risk of throm-
boemboli after cardioversion of atrial flutter may be “accept-
able” at 1%. It is 0%, however, for those receiving therapeutic
anticoagulation. Which risk would you rather have?
Data from the study of Gallagher et al. (5) confirm the
apparent risk of stroke in the cardioversion of atrial flutter.
The risk may actually be higher than that for cardioversion
of AF even though the two groups are not completely
comparable owing to differences in level of anticoagulation
and other risk factors. Based on these data, it is clearly
desirable for patients with atrial flutter (as with AF) to
undergo anticoagulation before cardioversion.
What is the level of anticoagulation needed to ensure
safety during and after cardioversion? The INR values
that ensure safety from thromboembolism in patients with
chronic atrial fibrillation may not apply to those undergoing
cardioversion. An INR between 2.0 and 3.0 has been
considered generally safer and effective (7). Based on avail-
able data and reasonable evidence, clinical guidelines now
state: “Administer anticoagulation therapy regardless of the
method (electrical or pharmacological) used to restore sinus
rhythm in patients with AF lasting48 hours or of unknown
duration for at least 3 to 4 weeks before and after cardioversion
(INR: 2 to 3)” (7). There is a rapid fall-off in efficacy as the
INR drops below 2.0, and there is increased risk of bleeding as
the INR exceeds 3.0. Gallagher et al. (5) challenge this
common wisdom and posit that the acceptable INR floor is
2.5. The data from the study of Gallagher et al. (5) call into
question an INR of 2.0 as an acceptable lower limit to prevent
stroke from cardioversion of AF.
Data from our laboratory on 532 consecutive patients
undergoing outpatient DC cardioversion of atrial flutter and
AF confirm that these recommendations are effective as
long as there is scrupulous attention to the INR value
(measured at least weekly for 3 weeks with INR values 
2.0 at each measurement) (21). No embolic events occurred
in those so anticoagulated. Some risk of stroke may always
be present with elective DC cardioversion of AF, but that
risk, far less than 1%, is now achievable.
An INR of 2.5 at the time of cardioversion may ensure
that recent INR values before cardioversion have remained
over 2.0, considering daily fluctuations. It is difficult to
ascertain what the INR values were in the 3 weeks before
cardioversion in the study of Gallagher et al. (5). Little
information is provided regarding the nine patients who had
thromboembolic events other than that their INR values
were 1.4 to 2.4. Two of these patients had no INR values
available, and of the nine patients with thromboembolic
events, some of the remaining seven may have had an INR
F.C. 2.0. It is surprising that the investigators used this
wide INR range, because it is well known that an INR2.0
places patients at risk. It is not clear how many patients in
the study of Gallagher et al. (5) had an INR between 2.0
and 2.4 and had a thromboembolic event. In only five
patients was the INR known at the time of the thrombo-
embolic event (INR: 1.7 to 2.5; mean, 2.1). No median
value is presented. The entire case recommending an INR
of 2.5 or more as a condition for stroke prevention could
hinge on two people with an INR2.0, with the remainder
having an INR2.0. Basing sweeping recommendations on
such a small subset is fraught with error. These few patients
may not be enough to mount a case to maintain an INR at
the level of 2.5. Is it safe for a patient to undergo cardio-
version with an INR measured at 2.1 for four consecutive
Figure 1. Head CT scan of a patient with chronic atrial fibrillation who
refused anticoagulation. The only symptom was dizziness—the tip of the
iceberg.
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weeks? This study does not answer that situation, but based
on data from our laboratory (21), it is safe.
Is heparin or low-molecular-weight heparin as safe and
as effective as warfarin for protection against thrombo-
emboli? Historically, heparin has been considered a surro-
gate for warfarin for AF. The two are not the same. The
risk/benefit ratio of heparin has not been carefully explored.
Despite recent guidelines that advocate its use (7), the efficacy
and safety of heparin anticoagulation are not well established
for AF. Interest in the use of low-molecular-weight heparin is
growing, and although it may be as effective as warfarin, more
information is needed before it can be recommended without
restraint.
What is the proper approach to anticoagulation for
patients who have cardioversion guided by TEE? Expe-
rience and studies supporting the use of TEE-guided
cardioversion (22) make anticoagulation issues even more
complex. It appears safe to cardiovert a patient with AF who
has no left atrial clot on TEE as long as anticoagulation is
undertaken at the time of cardioversion and thereafter.
Prospective, randomized data can be powerful, but as
Gallagher et al. (5) point out, their retrospective data are
more persuasive; they did not purposely exclude patients
undergoing cardioversion who do not fit into the trial.
Further, these data do conform to present clinical manage-
ment of patients with AF. It is unlikely that a prospective,
placebo-controlled, randomized clinical trial, testing effec-
tive anticoagulation schemes for cardioversion of atrial
arrhythmias, will materialize any time soon.
Cardioversion can be performed safely, but a high enough
level of anticoagulation must be assured, especially if AF or
atrial flutter lasts 48 h. It may be prudent to attempt to
raise the acceptable INR floor to 2.5 before cardioversion.
On the other hand, if careful, weekly assessments demon-
strate that the INR exceeds 2.0 consistently, then it is safe
to cardiovert (21). Data from Gallagher et al. (5) and others
highlight the importance of patients with atrial flutter and
AF undergoing anticoagulation before cardioversion (23).
The risk involved in cardioversion is improving. The risks
may improve further with better use of anticoagulation
regimens for AF and atrial flutter.
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